Coexistence of Translocation(1,19) and the Philadelphia Chromosome in a Child's First Presentation of Chronic Myeloid Leukemia in Blast Crisis Treated with Dasatinib

REFERENCES

• Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
   Google Scholar
• Johansson B, Billstrom R, Mauritzson N, Mitelman F. Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet. 1994;74:62–65.
   PubMedGoogle Scholar
• Kim JE, Woo KS, Kim KE, Duplications of the long arm of both chromosome 1, dup(1)(q21q32), leading to tetrasomy 1q in myelodysplastic syndrome. Leuk Res. 2010;34:e210–e212.
   PubMedGoogle Scholar
• Felice MS, Gallego MS, Alonso CN, Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols. Leuk Lymphoma. 2011;52:1215–1221.
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–4022.
   PubMed Web of Science ®Google Scholar
• Suttorp M, Claviez A, Bader P, Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr. 2009;221:351–357.
   PubMedGoogle Scholar
• Kantarjian H, O'Brien S, Cortes J, Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81–85.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian HM, O'Brien S, Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–2641.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, O'Brien S, Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Topaly J, Buss EC, Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–1549.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Goldman JM, International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM) [abstract]. Blood. 2008;112:76.
   Google Scholar
• Hughes TP, Hochhaus A, Branford S, Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–3765.
   PubMed Web of Science ®Google Scholar
• Gotoh M, Tauchi T, Yoshizawa S, Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation. Int J Hematol. 2010;91:128–131.
   PubMedGoogle Scholar
• Cortes J, Rousselot P, Kim DW, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207–3213.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22:2176–2183.
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D, Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–942.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28:398–404.
   PubMed Web of Science ®Google Scholar
• Werner M, Kaloutsi V, Buhr T, Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies. Ann Hematol. 1991;63:201–205.
   PubMed Web of Science ®Google Scholar
• Prigogina EL, Fleischman EW, Volkova MA, Frenkel MA. Chromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia. Hum Genet. 1978;41:143–156.
   PubMed Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.
   PubMed Web of Science ®Google Scholar
• Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102:1160–1168.
   PubMed Web of Science ®Google Scholar
• Jeha S, Pei D, Raimondi SC, Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia. 2009;23:1406–1409.
   PubMed Web of Science ®Google Scholar
• Casagrande G, te Kronnie G, Basso G. The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica. 2006;91:765–771.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Sensel MG, Sather HN, Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol. 1998;16:527–535.
   PubMed Web of Science ®Google Scholar
• Jung SI, Cho HS, Lee CH, Jung BC. A case of adult B lymphoblastic leukemia with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). Korean J Lab Med. 2010;30:585–590.
   PubMedGoogle Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.
   PubMed Web of Science ®Google Scholar
• Su XY, Wong N, Cao Q, Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21. Cancer Genet Cytogenet. 1999;108:6–12.
   PubMedGoogle Scholar